Evidence map›Paper›PMID 34262555›Full record

ArticleFrontiers in immunology2021

Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients.

Sarah Musa Hammoudeh, Arabella Musa Hammoudeh, Poorna Manasa Bhamidimarri, Habiba Al Safar, Bassam Mahboub, Axel Künstner, Hauke Busch, Rabih Halwani, Qutayba Hamid, Mohamed Rahmani and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. LILRA5Frontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Review
  8. Serum from COVID-19 patients promotes endothelial cell dysfunction through protease-activated receptor 2.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Article
  9. Article
  10. Article
  11. High risk of autoimmune diseases after COVID-19.Nature reviews. Rheumatology · 2023
    Article
  12. Expression ofFuture virology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Identification ofPharmacogenomics and personalized medicine · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah Musa HammoudehSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Arabella Musa HammoudehSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Poorna Manasa BhamidimarriSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Habiba Al SafarCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Bassam MahboubSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Axel KünstnerLuebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany.
Hauke BuschLuebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany.
Rabih HalwaniSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Qutayba HamidSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Mohamed RahmaniSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Rifat HamoudiSharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the current global health conundrums, COVID-19 pandemic caused a dramatic increase of cases exceeding 79 million and 1.7 million deaths worldwide. Severe presentation of COVID-19 is characterized by cytokine storm and chronic inflammation resulting in multi-organ dysfunction. Currently, it is unclear whether extrapulmonary tissues contribute to the cytokine storm mediated-disease exacerbation. In this study, we applied systems immunology analysis to investigate the immunomodulatory effects of SARS-CoV-2 infection in lung, liver, kidney, and heart tissues and the potential contribution of these tissues to cytokines production. Notably, genes associated with neutrophil-mediated immune response (e.g. CXCL1) were particularly upregulated in lung, whereas genes associated with eosinophil-mediated immune response (e.g. CCL11) were particularly upregulated in heart tissue. In contrast, immune responses mediated by monocytes, dendritic cells, T-cells and B-cells were almost similarly dysregulated in all tissue types. Focused analysis of 14 cytokines classically upregulated in COVID-19 patients revealed that only some of these cytokines are dysregulated in lung tissue, whereas the other cytokines are upregulated in extrapulmonary tissues (e.g. IL6 and IL2RA). Investigations of potential mechanisms by which SARS-CoV-2 modulates the immune response and cytokine production revealed a marked dysregulation of NF-κB signaling particularly CBM complex and the NF-κB inhibitor BCL3. Moreover, overexpression of mucin family genes (e.g. MUC3A, MUC4, MUC5B, MUC16, and MUC17) and HSP90AB1 suggest that the exacerbated inflammation activated pulmonary and extrapulmonary tissues remodeling. In addition, we identified multiple sets of immune response associated genes upregulated in a tissue-specific manner (DCLRE1C, CHI3L1, and PARP14 in lung; APOA4, NFASC, WIPF3, and CD34 in liver; LILRA5, ISG20, S100A12, and HLX in kidney; and ASS1 and PTPN1 in heart). Altogether, these findings suggest that the cytokines storm triggered by SARS-CoV-2 infection is potentially the result of dysregulated cytokine production by inflamed pulmonary and extrapulmonary (e.g. liver, kidney, and heart) tissues.

Indexed as

PandemicsSeverity of Illness IndexBiomarkersCase-Control StudiesCOVID-19Cytokine Release SyndromeCytokinesHumansImmunityKidneyLiverLungMonocytesMyocardiumNeutrophilsSARS-CoV-2BiomarkersCytokinesCOVID19cytokine stormextrapulmonary tissuesheartimmunopathogenesiskidneyliverSARS-CoV-2

Identifiers

PMID34262555
PMCPMC8273737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.